New biologic for the treatment of NHL packs one-two punch

Article

Clinicians can now offer their patients with non-Hodgkin?s lymphoma (NHL) therapy that combines targeted radiation with patient-specific dosing. The FDA recently approved tositumomab and iodine I-131 tositumomab (Bexxar, Corixa Corporation/GlaxoSmithKline) for the treatment of patients with CD20-positive, follicular NHL, with and without transformation, whose disease is refractory to rituxamab (Rituxan, Genentech) and has relapsed following chemotherapy. Training can be requested and orders placed by calling (877) 423-9927. Corixa recently began supplying Bexxar to cancer treatment centers.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.